Compare HCA Health Inc (HCA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Mesoblast Limited — how do they compare? HCA Health Inc trades at $443.69 (market cap $95.08B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: HCA Health Inc is far larger — about 52.5× Mesoblast Limited's market cap, and HCA Health Inc pays a 0.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Mesoblast Limited for 14 Days on average.
| HCA | MESO | |
|---|---|---|
Market Cap | $95.08B | $1.81B |
Volume | 998,787 | 240,620 |
Sector | Health | Health |
52-Week High | $545.13 | $20.96 |
52-Week Low | $361.32 | $13.19 |
Typical Hold Time | 76 Days | 14 Days |
Enterprise Value | $145.62B | $1.89B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
